BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 16821793)

  • 1. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
    Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
    J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
    Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
    J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
    Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
    J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
    Friedlos F; Denny WA; Palmer BD; Springer CJ
    J Med Chem; 1997 Apr; 40(8):1270-5. PubMed ID: 9111301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
    Hay MP; Wilson WR; Denny WA
    Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
    Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR
    Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
    Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
    Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
    Johansson E; Parkinson GN; Denny WA; Neidle S
    J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
    Mitchell DJ; Minchin RF
    Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
    Hu L; Wu X; Han J; Chen L; Vass SO; Browne P; Hall BS; Bot C; Gobalakrishnapillai V; Searle PF; Knox RJ; Wilkinson SR
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3986-91. PubMed ID: 21620697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture.
    Li Z; Han J; Jiang Y; Browne P; Knox RJ; Hu L
    Bioorg Med Chem; 2003 Sep; 11(19):4171-8. PubMed ID: 12951148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
    Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
    Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
    Jain M; Fan J; Baturay NZ; Kwon CH
    J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
    Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
    Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
    Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
    Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
    Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
    Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.